Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer

Scott D. Ramsey, Kristin Berry, Ruth Etzioni

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

OBJECTIVES: We aimed to determine cancer-related medical care costs for long term survivors of colorectal cancer. METHODS: The SEER-Medicare database was used to measure lifetime cancer-attributable costs of care for those with colorectal cancer surviving at least 5 yr versus age- and gender-matched controls. Costs were directly estimated, stratified by age at diagnosis and stage at diagnosis, for years 6-11 after diagnosis and then modeled to estimate lifetime costs. Cost differences between cancer cases and controls were compared to expected costs based on published guidelines for postcancer surveillance. RESULTS: Lifetime medical costs for long term survivors (future years not discounted) were up to $19,516 higher than control costs, and were highest for younger age groups and those with early-stage disease. Excess costs for cancer survivors exceeded expected surveillance costs by $2,223-8,822 for years 6-10 from the date of initial diagnosis. CONCLUSIONS: Cancer-attributable medical costs can be substantial for long term survivors, and exceed expected costs of surveillance. Future research is need to determine the components of excess cost in this survivor group.

Original languageEnglish (US)
Pages (from-to)440-445
Number of pages6
JournalAmerican Journal of Gastroenterology
Volume97
Issue number2
DOIs
StatePublished - Mar 2 2002
Externally publishedYes

Fingerprint

Survivors
Colorectal Neoplasms
Costs and Cost Analysis
Neoplasms
Cost Control
Medicare
Health Care Costs
Age Groups
Databases
Guidelines

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer. / Ramsey, Scott D.; Berry, Kristin; Etzioni, Ruth.

In: American Journal of Gastroenterology, Vol. 97, No. 2, 02.03.2002, p. 440-445.

Research output: Contribution to journalArticle

Ramsey, Scott D. ; Berry, Kristin ; Etzioni, Ruth. / Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer. In: American Journal of Gastroenterology. 2002 ; Vol. 97, No. 2. pp. 440-445.
@article{0653eebd36dd42d1b26cbaef595b6cf5,
title = "Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer",
abstract = "OBJECTIVES: We aimed to determine cancer-related medical care costs for long term survivors of colorectal cancer. METHODS: The SEER-Medicare database was used to measure lifetime cancer-attributable costs of care for those with colorectal cancer surviving at least 5 yr versus age- and gender-matched controls. Costs were directly estimated, stratified by age at diagnosis and stage at diagnosis, for years 6-11 after diagnosis and then modeled to estimate lifetime costs. Cost differences between cancer cases and controls were compared to expected costs based on published guidelines for postcancer surveillance. RESULTS: Lifetime medical costs for long term survivors (future years not discounted) were up to $19,516 higher than control costs, and were highest for younger age groups and those with early-stage disease. Excess costs for cancer survivors exceeded expected surveillance costs by $2,223-8,822 for years 6-10 from the date of initial diagnosis. CONCLUSIONS: Cancer-attributable medical costs can be substantial for long term survivors, and exceed expected costs of surveillance. Future research is need to determine the components of excess cost in this survivor group.",
author = "Ramsey, {Scott D.} and Kristin Berry and Ruth Etzioni",
year = "2002",
month = "3",
day = "2",
doi = "10.1016/S0002-9270(01)04045-X",
language = "English (US)",
volume = "97",
pages = "440--445",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Lifetime cancer-attributable cost of care for long term survivors of colorectal cancer

AU - Ramsey, Scott D.

AU - Berry, Kristin

AU - Etzioni, Ruth

PY - 2002/3/2

Y1 - 2002/3/2

N2 - OBJECTIVES: We aimed to determine cancer-related medical care costs for long term survivors of colorectal cancer. METHODS: The SEER-Medicare database was used to measure lifetime cancer-attributable costs of care for those with colorectal cancer surviving at least 5 yr versus age- and gender-matched controls. Costs were directly estimated, stratified by age at diagnosis and stage at diagnosis, for years 6-11 after diagnosis and then modeled to estimate lifetime costs. Cost differences between cancer cases and controls were compared to expected costs based on published guidelines for postcancer surveillance. RESULTS: Lifetime medical costs for long term survivors (future years not discounted) were up to $19,516 higher than control costs, and were highest for younger age groups and those with early-stage disease. Excess costs for cancer survivors exceeded expected surveillance costs by $2,223-8,822 for years 6-10 from the date of initial diagnosis. CONCLUSIONS: Cancer-attributable medical costs can be substantial for long term survivors, and exceed expected costs of surveillance. Future research is need to determine the components of excess cost in this survivor group.

AB - OBJECTIVES: We aimed to determine cancer-related medical care costs for long term survivors of colorectal cancer. METHODS: The SEER-Medicare database was used to measure lifetime cancer-attributable costs of care for those with colorectal cancer surviving at least 5 yr versus age- and gender-matched controls. Costs were directly estimated, stratified by age at diagnosis and stage at diagnosis, for years 6-11 after diagnosis and then modeled to estimate lifetime costs. Cost differences between cancer cases and controls were compared to expected costs based on published guidelines for postcancer surveillance. RESULTS: Lifetime medical costs for long term survivors (future years not discounted) were up to $19,516 higher than control costs, and were highest for younger age groups and those with early-stage disease. Excess costs for cancer survivors exceeded expected surveillance costs by $2,223-8,822 for years 6-10 from the date of initial diagnosis. CONCLUSIONS: Cancer-attributable medical costs can be substantial for long term survivors, and exceed expected costs of surveillance. Future research is need to determine the components of excess cost in this survivor group.

UR - http://www.scopus.com/inward/record.url?scp=0036178873&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036178873&partnerID=8YFLogxK

U2 - 10.1016/S0002-9270(01)04045-X

DO - 10.1016/S0002-9270(01)04045-X

M3 - Article

C2 - 11866285

AN - SCOPUS:0036178873

VL - 97

SP - 440

EP - 445

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 2

ER -